Among 507 patients with CDK4/6 amplifications, CCND1/2/3 amplifications, or CDKN2A/B alterations, 40 patients with diverse cancers (excluding patients with breast cancer) were treated with CDK4/6 inhibitor–containing regimens and evaluated for PFS (Figure 1 and Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.142547DS1). This evidence concerns the gene CDKN2A and breast cancer.